by Paul McIntosh | Feb 26, 2021 | 2021, Press Releases
Aberdeen, UK – 26th February 2021 – NovaBiotics Ltd, the clinical-stage anti-infectives biotechnology company, today announced that it has entered into a licensing agreement with an undisclosed partner to commercialise its NP213 peptide in a topical (brush/paint-on)...
by Paul McIntosh | Feb 2, 2021 | 2021, Events
CEO Dr Deborah O’Neil and the NovaBiotics team will be attending the BIO CEO & Investor Conference, hosted by the Biotechnology Innovation Organization on the 16th-18th February 2021. Meet with us through the event portal BIO CEO & Investor Event to...
by Paul McIntosh | Dec 31, 2020 | 2020, Blog Post
By Grant Ellis, Director NovaBiotics Ltd Back in October I quoted Sir Patrick Vallance, the government’s Chief Scientific Adviser saying that no vaccine for Covid was likely before the spring of 2021. We all now know that there are two vaccines that have been...
by Paul McIntosh | Dec 29, 2020 | 2020, Press Releases
NovaBiotics are delighted to announce that our CARE CF 1 phase 2b clinical trial data for oral Lynovex in infectious pulmonary exacerbations of cystic fibrosis is published today in PLOS ONE. Our findings further support the potential of Lynovex® as game-changer in CF...
by Paul McIntosh | Dec 28, 2020 | 2020, Press Releases, Uncategorized
NovaBiotics featured in an article published in the Mail on Sunday on 27 December 2020 entitled “British scientists are engineering superbug-beating medications to fight off killer infections including MRSA.” See the full article by clicking Mail on Sunday Article 27...
Recent Comments